Searchable abstracts of presentations at key conferences in endocrinology

ea0011oc58 | ThyroidOC57 British Thyroid Association Award | ECE2006

Interleukin 1: the optimal cytokine target in thyroid associated ophthalmopathy?

Cawood TJ , Moriaty P , O’Farrelly C , O’Shea D

Introduction: Anti-cytokine therapy may be useful for the treatment of active thyroid associated ophthalmopathy (TAO). We aimed to establish the effects of selected cytokines on intercellular adhesion molecule 1 (ICAM1) expression and adipogenesis in orbital fibroblasts (OFs) from patients with and without TAO.Methods: Orbital tissue was taken during surgery from 5 patients with TAO and 5 control subjects. Primary cultures of OFs were established and sta...

ea0026p251 | Pituitary | ECE2011

Lost to follow-up in acromegaly, results of ACROSPECT observational study

Delemer B D , Reines C R , Brue T B , Rudelli C C Cortet , Raingeard I R , Reznik Y R , Parot X P , Chabre O C

Lost to follow-up (LTFU) is a frequent problem in chronic diseases not evaluated yet in acromegaly despite the long-term need of medical treatment and complications survey in this disease.Objectives: Evaluation of the prevalence of LTFU patients in a multi-center cohort, characteristics of defaulters and description of their evolution after they have been searched and found.Méthods: Observational multicentric (25 centers study...

ea0095p89 | Bone 2 | BSPED2023

Establishing reference interval values of fibroblast growth factor 23 in paediatrics population

Chu Andre O C , Piec Isabelle , Fraser William D , Dunn Rachel , Farag Amrou , Chipchase Allison , Tang Jonathan C Y , Webb Emma

Background: Fibroblast growth factor 23 (FGF23) is a key protein in bone homeostasis regulatingserumphosphateand calcitriol (1,25(OH)2D3) concentrations. Analytical performance and reference ranges of FGF23 assays differ by molecule assayed (intact or C-terminal FGF23) and manufacturer. We aim to establish reference interval values for both cFGF23 and iFGF23 in a paediatric population.Methods: Writt...

ea0026p30 | Adrenal cortex | ECE2011

Is plasma mitotane level >30 mg/l a serious adverse event in patients with adrenocortical carcinoma (ACC)?: a retrospective analysis of the French COMETE network

Mauclere-Denost S M D , Tabarin A T , Drui D D , Chaillous L C , Salenave S S , Leboulleux S L , Chabre O C , Do-Cao C D C , Dubourg H D , Cuvelier M L C , Young J Y , Baudin E B

Background: Mitotane antitumor efficacy is related to plasma levels. Objective responses have been associated with mitotane plasma levels >14 mg/l. However, high plasma levels >20 or >30 mg/l are at higher risk of toxicity, especially neurotoxicity. National-based survey is lacking to evaluate the frequency and severity of high mitotane plasma levels. Our aim was to retrospectively describe serious adverse events (SAE).Methods: Mitotane plasm...